Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 12/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056535 | 0.84 | HSD17B10 (0.41) | HSD17B10NPC1 | |
| SCHEMBL3604405 | 0.84 | HSD17B10 (0.41) | HSD17B10NPC1 | |
| SCHEMBL3607611 | 0.83 | DPP4 (0.38) | HSD17B10 | |
| SCHEMBL3597534 | 0.83 | RAB9A (0.40) | OPRM1CNR2RORC | |
| SCHEMBL25496865 | 0.74 | HDAC8 (0.45) | OPRM1CNR2HDAC8 | |
| SCHEMBL22280077 | 0.74 | HDAC8 (0.45) | OPRM1CNR2HDAC8 | |
| SCHEMBL1347670 | 0.74 | CNR2 (0.39) | CNR2HDAC8HSD17B10CNR1 | |
| SCHEMBL6468015 | 0.74 | CNR2 (0.39) | CNR2HDAC8HSD17B10CNR1 | |
| SCHEMBL15130409 | 0.74 | CNR2 (0.39) | CNR2HDAC8HSD17B10CNR1 | |
| SCHEMBL15130403 | 0.73 | HDAC8 (0.46) | CNR2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | OPRM1 4765/4885CNR2 4825/4885RORC 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.